MedTrace Logo

Single Ascending Dose Study With 5-MeO-DMT in Healthy Subjects

NCT05032833 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2022-10-12

No results posted yet for this study

Summary

The study will evaluate safety, tolerability and PK profile of 5-MeO-DMT in healthy subjects

Conditions

  • Pharmacokinetics in Healthy Adults

Interventions

DRUG

5-MeO-DMT

A single dose of 5-MeO-DMT will be administered intranasally

OTHER

Placebo

A single dose of placebo will be administered intranasally

Sponsors & Collaborators

  • Beckley Psytech Limited

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
25 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-09-22
Primary Completion
2022-07-07
Completion
2022-07-07

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05032833 on ClinicalTrials.gov